Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H14F3N3O3 |
Molecular Weight | 389.328 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@](O)(COC1=CC=C(C=C1)C#N)C(=O)NC2=CC=C(C#N)C(=C2)C(F)(F)F
InChI
InChIKey=JNGVJMBLXIUVRD-SFHVURJKSA-N
InChI=1S/C19H14F3N3O3/c1-18(27,11-28-15-6-2-12(9-23)3-7-15)17(26)25-14-5-4-13(10-24)16(8-14)19(20,21)22/h2-8,27H,11H2,1H3,(H,25,26)/t18-/m0/s1
Molecular Formula | C19H14F3N3O3 |
Molecular Weight | 389.328 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/19852734https://www.ncbi.nlm.nih.gov/pubmed/24490605Curator's Comment: Description was created based on several sources, including
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19852734https://www.ncbi.nlm.nih.gov/pubmed/24490605
Curator's Comment: Description was created based on several sources, including
Enobosarm, also known as ostarine, is an investigational selective androgen receptor modulator (SARM) from GTX, Inc for treatment of conditions such as muscle wasting and osteoporosis. Enobosarm has been tested in Phase I, II and III trials with promising results in terms of improving lean body mass and measurements of physical function and power. Enobosarm has received fast track designation by the US FDA. Enobosarm is a selective androgen receptor modulator (SARM) with Ki of 3.8 nM, and is tissue-selective for anabolic organs. It is in Phase II for Breast cancer and Stress incontinence and discontinued for Cachexia and Muscular atrophy.
Originator
Sources: http://www.merck.com/licensing/news-and-events/gtx-press-release.htmlhttp://adisinsight.springer.com/drugs/800022562
Curator's Comment: # GTx and Merck & Co., Inc.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1871 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15987833 |
3.8 nM [Ki] | ||
Target ID: CHEMBL1871 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26393303 |
3.8 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
57.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27105861 |
3 mg 1 times / day single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered: |
ENOBOSARM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
779.5 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27105861 |
3 mg 1 times / day single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered: |
ENOBOSARM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
22 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27105861 |
3 mg 1 times / day single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered: |
ENOBOSARM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
3 mg 1 times / day multiple, oral Highest studied dose Dose: 3 mg, 1 times / day Route: oral Route: multiple Dose: 3 mg, 1 times / day Sources: Page: p.155 |
healthy, ADULT n = 24 Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 24 Sources: Page: p.155 |
Disc. AE: ALT increased... AEs leading to discontinuation/dose reduction: ALT increased (4.2%) Sources: Page: p.155 |
3 mg 1 times / day multiple, oral Highest studied dose Dose: 3 mg, 1 times / day Route: oral Route: multiple Dose: 3 mg, 1 times / day Sources: Page: p.7 |
unhealthy, ADULT n = 54 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 54 Sources: Page: p.7 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
ALT increased | 4.2% Disc. AE |
3 mg 1 times / day multiple, oral Highest studied dose Dose: 3 mg, 1 times / day Route: oral Route: multiple Dose: 3 mg, 1 times / day Sources: Page: p.155 |
healthy, ADULT n = 24 Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 24 Sources: Page: p.155 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no | ||||
yes [IC50 1.31 uM] | yes (co-administration study) Comment: Increased rosubastatin Cmax and AUCinf by 29% and 18%. Sources: https://pubmed.ncbi.nlm.nih.gov/27105861/ |
|||
yes [IC50 1.6 uM] | yes (co-administration study) Comment: Decreased celecoxib Cmax and AUCinf by 13% and 10%. Sources: https://pubmed.ncbi.nlm.nih.gov/27105861/ |
|||
yess [IC50 0.7 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | yes (co-administration study) Comment: Rifampicin decreased Cmax and AUCinf by 23% and 43%. Sources: https://pubmed.ncbi.nlm.nih.gov/27105861/ |
|||
major | yes (co-administration study) Comment: Probenecid increased AUCinf by 50% and decreased Cmax by 6.7%. Sources: https://pubmed.ncbi.nlm.nih.gov/27105861/ |
|||
major | yes (co-administration study) Comment: Probenecid increased AUCinf by 50% and decreased Cmax by 6.7%. Sources: https://pubmed.ncbi.nlm.nih.gov/27105861/ |
|||
minor | ||||
minor | ||||
minor | ||||
minor | ||||
minor | ||||
minor | ||||
minor | ||||
no | ||||
no | ||||
no |
PubMed
Title | Date | PubMed |
---|---|---|
Nonsteroidal selective androgen receptor modulator Ostarine in cancer cachexia. | 2009 Oct |
|
Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. | 2013 Apr |
|
Absorption, distribution, metabolism and excretion of the novel SARM GTx-024 [(S)-N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide] in rats. | 2013 Nov |
|
Enobosarm (GTx-024) Modulates Adult Skeletal Muscle Mass Independently of the Androgen Receptor in the Satellite Cell Lineage. | 2015 Dec |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23499390
1 or 3 mg Gtx-024 once daily for 16 weeks in patients with cancer induced muscle loss, (cancer cachexia)
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.selleckchem.com/products/Ostarine.html
Enobosarm at the concentration of 10 nM modulates the transcriptional activity of AR in CV-1 cells cotransfected with a human AR expression vector, a luciferase reporter vector, and a control β-galactosidase vector, with 94%-100% relative activity of the transcriptional activation observed for 1 nM DHT.
Substance Class |
Chemical
Created
by
admin
on
Edited
Thu Jul 06 22:22:28 UTC 2023
by
admin
on
Thu Jul 06 22:22:28 UTC 2023
|
Record UNII |
O3571H3R8N
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DSLD |
3985 (Number of products:13)
Created by
admin on Thu Jul 06 22:22:28 UTC 2023 , Edited by admin on Thu Jul 06 22:22:28 UTC 2023
|
||
|
WIKIPEDIA |
Designer-drugs-Enobosarm
Created by
admin on Thu Jul 06 22:22:28 UTC 2023 , Edited by admin on Thu Jul 06 22:22:28 UTC 2023
|
||
|
NCI_THESAURUS |
C147920
Created by
admin on Thu Jul 06 22:22:28 UTC 2023 , Edited by admin on Thu Jul 06 22:22:28 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID30233006
Created by
admin on Thu Jul 06 22:22:28 UTC 2023 , Edited by admin on Thu Jul 06 22:22:28 UTC 2023
|
PRIMARY | |||
|
O3571H3R8N
Created by
admin on Thu Jul 06 22:22:28 UTC 2023 , Edited by admin on Thu Jul 06 22:22:28 UTC 2023
|
PRIMARY | |||
|
9596
Created by
admin on Thu Jul 06 22:22:28 UTC 2023 , Edited by admin on Thu Jul 06 22:22:28 UTC 2023
|
PRIMARY | |||
|
100000168546
Created by
admin on Thu Jul 06 22:22:28 UTC 2023 , Edited by admin on Thu Jul 06 22:22:28 UTC 2023
|
PRIMARY | |||
|
CHEMBL1738889
Created by
admin on Thu Jul 06 22:22:28 UTC 2023 , Edited by admin on Thu Jul 06 22:22:28 UTC 2023
|
PRIMARY | |||
|
841205-47-8
Created by
admin on Thu Jul 06 22:22:28 UTC 2023 , Edited by admin on Thu Jul 06 22:22:28 UTC 2023
|
PRIMARY | |||
|
YY-84
Created by
admin on Thu Jul 06 22:22:28 UTC 2023 , Edited by admin on Thu Jul 06 22:22:28 UTC 2023
|
PRIMARY | |||
|
ENOBOSARM
Created by
admin on Thu Jul 06 22:22:28 UTC 2023 , Edited by admin on Thu Jul 06 22:22:28 UTC 2023
|
PRIMARY | |||
|
11326715
Created by
admin on Thu Jul 06 22:22:28 UTC 2023 , Edited by admin on Thu Jul 06 22:22:28 UTC 2023
|
PRIMARY | |||
|
DB12078
Created by
admin on Thu Jul 06 22:22:28 UTC 2023 , Edited by admin on Thu Jul 06 22:22:28 UTC 2023
|
PRIMARY | |||
|
SUB182072
Created by
admin on Thu Jul 06 22:22:28 UTC 2023 , Edited by admin on Thu Jul 06 22:22:28 UTC 2023
|
PRIMARY | |||
|
2168587
Created by
admin on Thu Jul 06 22:22:28 UTC 2023 , Edited by admin on Thu Jul 06 22:22:28 UTC 2023
|
PRIMARY | |||
|
C69161
Created by
admin on Thu Jul 06 22:22:28 UTC 2023 , Edited by admin on Thu Jul 06 22:22:28 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST |
SARM
BINDING
Ki
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|